Literature DB >> 29679953

Antinociception by the anti-oxidized phospholipid antibody E06.

Milad Mohammadi1, Beatrice Oehler1,2, Jan Kloka1,2, Corinna Martin2, Alexander Brack1, Robert Blum2, Heike L Rittner1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29679953      PMCID: PMC6016623          DOI: 10.1111/bph.14340

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  85 in total

1.  Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.

Authors:  Paul J Tiseo; Alan J Kivitz; John E Ervin; Haobo Ren; Scott J Mellis
Journal:  Pain       Date:  2014-03-29       Impact factor: 6.961

Review 2.  Reactive oxygen species in inflammation and tissue injury.

Authors:  Manish Mittal; Mohammad Rizwan Siddiqui; Khiem Tran; Sekhar P Reddy; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2013-10-22       Impact factor: 8.401

Review 3.  TRPA1 channels: molecular sentinels of cellular stress and tissue damage.

Authors:  Félix Viana
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

4.  Antinociception by the anti-oxidized phospholipid antibody E06.

Authors:  Milad Mohammadi; Beatrice Oehler; Jan Kloka; Corinna Martin; Alexander Brack; Robert Blum; Heike L Rittner
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

5.  Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain.

Authors:  Jeannette Endres-Becker; Paul A Heppenstall; Shaaban A Mousa; Dominika Labuz; Alexander Oksche; Michael Schäfer; Christoph Stein; Christian Zöllner
Journal:  Mol Pharmacol       Date:  2006-09-27       Impact factor: 4.436

6.  Hydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanisms.

Authors:  Julie Elizabeth Keeble; Jennifer Victoria Bodkin; Lihuan Liang; Rachel Wodarski; Meirion Davies; Elizabeth Soares Fernandes; Carly de Faria Coelho; Fiona Russell; Rabea Graepel; Marcelo Nicolas Muscara; Marzia Malcangio; Susan Diana Brain
Journal:  Pain       Date:  2008-12-06       Impact factor: 6.961

Review 7.  Molecular sensors and modulators of thermoreception.

Authors:  Xuming Zhang
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

Review 8.  Protein modification by aldehydophospholipids and its functional consequences.

Authors:  Ute Stemmer; Albin Hermetter
Journal:  Biochim Biophys Acta       Date:  2012-03-16

9.  Muscle Reactive Oxygen Species (ROS) Contribute to Post-Incisional Guarding via the TRPA1 Receptor.

Authors:  Daisuke Sugiyama; Sinyoung Kang; Timothy J Brennan
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

10.  HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity.

Authors:  Samer R Eid; Eric D Crown; Eric L Moore; Hongyu A Liang; Kar-Chan Choong; Shelley Dima; Darrell A Henze; Stefanie A Kane; Mark O Urban
Journal:  Mol Pain       Date:  2008-10-27       Impact factor: 3.395

View more
  3 in total

1.  Antinociception by the anti-oxidized phospholipid antibody E06.

Authors:  Milad Mohammadi; Beatrice Oehler; Jan Kloka; Corinna Martin; Alexander Brack; Robert Blum; Heike L Rittner
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

2.  D-4F, an ApoA-I mimetic peptide ameliorating TRPA1-mediated nocifensive behaviour in a model of neurogenic inflammation.

Authors:  Beatrice Oehler; Jan Kloka; Milad Mohammadi; Adel Ben-Kraiem; Heike L Rittner
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

Review 3.  Pain Control by Targeting Oxidized Phospholipids: Functions, Mechanisms, Perspectives.

Authors:  Beatrice Oehler; Alexander Brack; Robert Blum; Heike L Rittner
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-25       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.